Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS

Other illness

• Known clinically manifest cardiovascular disease
• Estimated glomerular filtration rate of \<45 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration equation
• Severe liver disease or cirrhosis
• History of any other malignancy within the past 5 years in addition to melanoma with the exception of non-melanoma skin cancers
• Evidence of any other clinically significant non-cardiac disease or condition that, in the opinion of the Investigator, would preclude participation in the study
• Major allergy to iodine

Other

• Female participants must not be pregnant, breastfeeding or plan to become pregnant during the study.
• Prognostic factors associated with an expected survival less than 18 months at Investigators' discretion (e.g. unresectable brain metastases)
• Participation in another clinical trial that does not allow participation in multiple trials at the same time

• Capable of providing informed consent and willing to adhere to all protocol requirements
• patients aged \> or equal to 40 years
• Histologically confirmed melanoma of any stage planned for, commenced, or completed treatment with ICI
• having acceptable imaging quality deemed by the core laboratory
• Investigator believes that the participant is willing to adhere to all protocol requirements, including returning for follow up CTCA.